Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600903921> ?p ?o ?g. }
- W2600903921 endingPage "267" @default.
- W2600903921 startingPage "256" @default.
- W2600903921 abstract "The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR. This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies. Most of the TKR share intracellular signaling pathways; therefore, cancer cells tend to overcome the inhibition of one tyrosine kinase receptor by activating another. The future of TKI (Tyrosine Kinase Inhibitor) therapy will potentially come from multi-targeted TKIs that target different TKR simultaneously. It is crucial to understand the interaction of the FGF-FGFR axis with other known driver TKRs. Based on this, it is possible to develop therapeutic strategies targeting multiple connected TKRs at once. One correct step in this direction is the reassessment of multi target inhibitors considering the FGFR status of the tumor. Another opportunity arises from assessing the use of FGFR TKI on patients harboring FGFR alterations." @default.
- W2600903921 created "2017-04-07" @default.
- W2600903921 creator A5002054732 @default.
- W2600903921 creator A5004737640 @default.
- W2600903921 creator A5004941240 @default.
- W2600903921 creator A5005436649 @default.
- W2600903921 creator A5012217732 @default.
- W2600903921 creator A5014945042 @default.
- W2600903921 creator A5019133779 @default.
- W2600903921 creator A5026095888 @default.
- W2600903921 creator A5051002285 @default.
- W2600903921 creator A5057135904 @default.
- W2600903921 creator A5070137528 @default.
- W2600903921 creator A5074157871 @default.
- W2600903921 creator A5074318514 @default.
- W2600903921 creator A5074506844 @default.
- W2600903921 date "2017-05-01" @default.
- W2600903921 modified "2023-10-17" @default.
- W2600903921 title "FGFR a promising druggable target in cancer: Molecular biology and new drugs" @default.
- W2600903921 cites W1427072199 @default.
- W2600903921 cites W1513451331 @default.
- W2600903921 cites W1538622944 @default.
- W2600903921 cites W1566932673 @default.
- W2600903921 cites W1571830205 @default.
- W2600903921 cites W1619165052 @default.
- W2600903921 cites W1630482321 @default.
- W2600903921 cites W1765107706 @default.
- W2600903921 cites W1854073441 @default.
- W2600903921 cites W1858027700 @default.
- W2600903921 cites W1964015222 @default.
- W2600903921 cites W1968209756 @default.
- W2600903921 cites W1975685675 @default.
- W2600903921 cites W1977667517 @default.
- W2600903921 cites W1979702889 @default.
- W2600903921 cites W1992137373 @default.
- W2600903921 cites W1993602044 @default.
- W2600903921 cites W1994075309 @default.
- W2600903921 cites W1996958662 @default.
- W2600903921 cites W1998338586 @default.
- W2600903921 cites W2005792607 @default.
- W2600903921 cites W2005795386 @default.
- W2600903921 cites W2007560515 @default.
- W2600903921 cites W2011911766 @default.
- W2600903921 cites W2011993967 @default.
- W2600903921 cites W2019711215 @default.
- W2600903921 cites W2024650311 @default.
- W2600903921 cites W2024896457 @default.
- W2600903921 cites W2025533780 @default.
- W2600903921 cites W2027239974 @default.
- W2600903921 cites W2028202571 @default.
- W2600903921 cites W2030500412 @default.
- W2600903921 cites W2031563027 @default.
- W2600903921 cites W2035742026 @default.
- W2600903921 cites W2037819581 @default.
- W2600903921 cites W2047320857 @default.
- W2600903921 cites W2054020870 @default.
- W2600903921 cites W2055560819 @default.
- W2600903921 cites W2056983875 @default.
- W2600903921 cites W2059933457 @default.
- W2600903921 cites W2060563871 @default.
- W2600903921 cites W2064140109 @default.
- W2600903921 cites W2066059461 @default.
- W2600903921 cites W2068549807 @default.
- W2600903921 cites W2072737626 @default.
- W2600903921 cites W2079289956 @default.
- W2600903921 cites W2080515137 @default.
- W2600903921 cites W2085919694 @default.
- W2600903921 cites W2088872576 @default.
- W2600903921 cites W2091076857 @default.
- W2600903921 cites W2091856405 @default.
- W2600903921 cites W2093090488 @default.
- W2600903921 cites W2095509444 @default.
- W2600903921 cites W2096019143 @default.
- W2600903921 cites W2096861064 @default.
- W2600903921 cites W2097373408 @default.
- W2600903921 cites W2098320019 @default.
- W2600903921 cites W2098466520 @default.
- W2600903921 cites W2100374586 @default.
- W2600903921 cites W2107977954 @default.
- W2600903921 cites W2108285390 @default.
- W2600903921 cites W2116215301 @default.
- W2600903921 cites W2116368558 @default.
- W2600903921 cites W2124912399 @default.
- W2600903921 cites W2127990562 @default.
- W2600903921 cites W2128288739 @default.
- W2600903921 cites W2129566355 @default.
- W2600903921 cites W2130787560 @default.
- W2600903921 cites W2131088620 @default.
- W2600903921 cites W2136873201 @default.
- W2600903921 cites W2136950355 @default.
- W2600903921 cites W2141416577 @default.
- W2600903921 cites W2142702787 @default.
- W2600903921 cites W2144651981 @default.
- W2600903921 cites W2148682310 @default.
- W2600903921 cites W2149792874 @default.
- W2600903921 cites W2151600653 @default.
- W2600903921 cites W2153089464 @default.
- W2600903921 cites W2153997364 @default.